Cancer molecular diagnostics specialist GENCURIX announced on 2nd that it will expand its breast cancer prognosis diagnostic test previously offered at advanced general hospitals to secondary general hospitals.
GENCURIX received approval for additional use of its breast cancer prognosis diagnostic test at 15 secondary general hospitals as conducting institutions from the National Evidence-based Healthcare Collaborating Agency (NECA). This is in accordance with the revised announcement for innovative medical technology, allowing the use of unapproved testing institutions for genetic testing.
The breast cancer prognosis diagnostic test "Jinswell BCT" is the first test developed for Asians in Asia. It is the only one in the country that has obtained manufacturing and item approval from the Ministry of Food and Drug Safety. Jinswell BCT can be covered by actual loss insurance, thereby reducing the economic burden on patients.
GENCURIX has previously announced research results proving its excellence through comparative studies with breast cancer prognosis diagnostic products from the United States at conferences such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Last year, despite the impact of strikes in the medical sector, the number of hospitals introducing Jinswell BCT continued to increase.
Choi Chung-yeol, head of the diagnostic medicine division at GENCURIX, noted, "Jinswell BCT has established itself as a domestic product replacing U.S. breast cancer prognosis diagnostic products that have led the domestic market. This year, we will accelerate our global market expansion through collaboration with various Asian medical institutions, including those in China and Japan."